Tolterodine: As effective but better tolerated than oxybutynin in Asian patients with symptoms of overactive bladder

Jeong Gu Lee, Jae Yup Hong, Myung Soo Choo, Hun Young Kwon, Do Young Chung, Kyu Sung Lee, Ji Youl Lee, Tack Lee

Research output: Contribution to journalArticlepeer-review

51 Citations (Scopus)


Background: This double-blind, multicenter study compared the efficacy and tolerability of tolterodine (Pharmacia, Los Angeles, USA) with that of oxybutynin (Alza, Palo Alto, USA) in Asian patients with overactive bladder. Methods: Two-hundred-and-twenty-eight adults with overactive bladder symptoms were randomized to receive tolterodine 2 mg twice daily (bid) (n = 112) or oxybutynin 5 mg bid (n = 116). After 8 weeks' treatment, changes in micturition diary variables, patients' perception of treatment benefit, and tolerability endpoints were determined. Results: The mean (±SD) number of micturitions/24 h decreased by 2.6 ± 2.9 (-21%) with tolterodine and 1.8 ± 4.2 (-15%) with oxybutynin (both P = 0.0001 vs baseline). The mean number of incontinence episodes/24 h decreased by 2.2 ± 2.3 (-85%) in the tolterodine group and by 1.4 ± 1.8 (-58%) in the oxybutynin group (both P = 0.0001 vs baseline). Patient perception of treatment benefit was over 70% in each treatment group. Adverse events were significantly lower in the tolterodine group compared with oxybutynin-treated patients (55% vs 82%; P = 0.001). Dry mouth was reported by significantly fewer patients on tolterodine, compared with oxybutynin (35% vs 63%; P = 0.001) and withdrawals due to adverse events were lower in the tolterodine group than with those treated with oxybutynin (10% vs 16%). There were no safety concerns. Conclusions: Tolterodine 2 mg bid is equally or more effective than oxybutynin 5 mg bid in the treatment of Asian patients with overactive bladder, and shows significantly better tolerability. This may enhance compliance during long-term treatment.

Original languageEnglish
Pages (from-to)247-252
Number of pages6
JournalInternational Journal of Urology
Issue number5
Publication statusPublished - 2002
Externally publishedYes


  • Overactive bladder
  • Oxybutynin
  • Tolterodine

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'Tolterodine: As effective but better tolerated than oxybutynin in Asian patients with symptoms of overactive bladder'. Together they form a unique fingerprint.

Cite this